very bright future, page-22

It is amazing how the reaction one can draw when stating the truth, at least from their point of view, It is very similar every where you look.

Personal in nature that is, with the respondents not bothering to even discuss the company's business or stating facts for the sake of a better discussion.

And it doesn't matter who the respondents are, UN worthy individuals, or otherwise very simple ones.

But I won't go there anymore, accusations can be thrown both ways mind you, and for some good reasons. but I would rather focus on the more factual and hopefully smarter side of the argument, and if that ends up as a one sided one, it is a choice for the others to make.

12 healthy young males went into phase 2 trails, 4 placebo and 8 on medication, 2 withdrawn, so assuming 1 of the medicated group withdrawn then we have 7 left.

one out of seven had Temp. high ALT levels, that is nearly 15%. and considering the short time frame and very limited dosage, I think I have the right to question weather this is something will show up as a serious problem later during a larger scale trials, over longer period of time.

And that is how the market thinks, look we have some results here, but we need to make sure this is a safe drug longer term before any serious deal can be struck, or if we do one now, the risk will be represented in the offer.

That is why ANP is not a few hundred million dollars company " before Xmas" as some suggested. but in a strange and wonderful world such bizarre valuations were considered honest and praised with being the result of "good research".

But the market decided which side of the argument won, the intelligent argument mind you, not the shouting and personally targeted one.

Well, at least so far!


It is true ALT levels went down again before the next dose, but remember those were healthy young volunteers and received only 6 dosages, many acromegaly patients will be less healthy, on lots of other medications, especially on chemotherapy. and therefore their livers will be more sensitive to any potential side effects of ATL1103.

I am hoping that some here can understand the negative affect of chemotherapy on the liver. which might be prescribed to control many patients brain tumors.

And that is why I said before, stage one is a step, but it means nothing if toxicology showed up to be an issue in the future, and that is why the market will wait and see stage 2 results before deciding to write ALT1103 the big cheque that a lot here were so certain of getting so very soon.

But that is some months away if ever, and at 3 to 4 cents ALT1103 result is more than factored in the share price in my view.

Noticed the directors lack of enthusiasm for the current licensing discussions, I guess they are not getting the kind of offer that "they can't refuse", and I ask myself why. if an offer of that magnitude was made, it would have been accepted already. but instead the directors are clearly preparing themselves and shareholders for second phase trials with the cost and the risks associated with it.

The above is related to ATL1103 and its current results only. and not taking into account any potential Afendin agreement.

Have a good day!